Publicacións nas que colabora con Paula Peleteiro Higuero (14)

2023

  1. Large-scale meta-genome-wide association study reveals common genetic factors linked to radiation-induced acute toxicities across cancer types

    JNCI Cancer Spectrum, Vol. 7, Núm. 6

2022

  1. Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): results of the ANARESISTANCE study

    World Journal of Urology, Vol. 40, Núm. 10, pp. 2459-2466

2019

  1. Are there enough radiation oncologists to lead the new Spanish radiotherapy?

    Clinical and Translational Oncology, Vol. 21, Núm. 12, pp. 1663-1672

  2. Erratum to: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (Nature Communications, (2018), 9, 1, (4616), 10.1038/s41467-018-06863-1)

    Nature Communications

  3. REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer

    Radiotherapy and Oncology, Vol. 138, pp. 59-67

2018

  1. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants

    Nature Communications, Vol. 9, Núm. 1

  2. Germline variation at 8q24 and prostate cancer risk in men of European ancestry

    Nature Communications, Vol. 9, Núm. 1

2016

  1. Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer

    EBioMedicine, Vol. 10, pp. 150-163

2015

  1. Cáncer de recto localmente avanzado. La necesidad de la superespecialización

    Revista Colombiana de Cancerología, Vol. 19, Núm. 3, pp. 180-183

2014

  1. A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1

    Nature Genetics, Vol. 46, Núm. 8, pp. 891-894

2012

  1. Association of a XRCC3 polymorphism and rectum mean dose with the risk of acute radio-induced gastrointestinal toxicity in prostate cancer patients

    Radiotherapy and Oncology, Vol. 105, Núm. 3, pp. 321-328

  2. Calidad de vida después recidiva bioquímica en los pacientes con cáncer de próstata. ¿Cómo y cuánto viven los pacientes después de recidiva bioquímica?

    Archivos Espanoles de Urologia, Vol. 65, Núm. 1, pp. 193-206

  3. TGFβ1 SNPs and radio-induced toxicity in prostate cancer patients

    Radiotherapy and Oncology, Vol. 103, Núm. 2, pp. 206-209

2011

  1. BRCA1 mutations do not increase prostate cancer risk: Results from a meta-analysis including new data

    Prostate, Vol. 71, Núm. 16, pp. 1768-1779